Ironwood Pharmaceuticals, Inc.
NASDAQ:IRWD
4.51 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 442.735 | 410.596 | 413.753 | 389.523 | 428.413 | 346.639 | 298.276 | 273.957 | 149.555 | 76.436 | 22.881 | 150.245 | 65.871 | 43.857 | 36.102 | 22.216 | 10.464 |
| Cost of Revenue
| 1.575 | 1.418 | 1.523 | 3.136 | 23.875 | 32.751 | 19.406 | 1.868 | 0.012 | 25.583 | 7.203 | 0.965 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 441.16 | 409.178 | 412.23 | 386.387 | 404.538 | 313.888 | 278.87 | 272.089 | 149.543 | 50.853 | 15.678 | 149.28 | 65.871 | 43.857 | 36.102 | 22.216 | 10.464 |
| Gross Profit Ratio
| 0.996 | 0.997 | 0.996 | 0.992 | 0.944 | 0.906 | 0.935 | 0.993 | 1 | 0.665 | 0.685 | 0.994 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 99.41 | 44.265 | 70.405 | 88.062 | 115.044 | 166.503 | 148.228 | 139.492 | 108.746 | 101.89 | 102.378 | 113.474 | 86.093 | 77.454 | 84.892 | 59.809 | 57.246 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 241.291 | 233.123 | 173.281 | 125.247 | 118.333 | 123.228 | 92.538 | 45.92 | 27.169 | 23.98 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 132.714 | 115.994 | 111.133 | 140.003 | 172.45 | 241.291 | 233.123 | 173.281 | 125.247 | 118.333 | 123.228 | 92.538 | 45.92 | 27.169 | 23.98 | 18.328 | 10.833 |
| Other Expenses
| 0 | 0 | 0 | 0.024 | 0.514 | 8.111 | 6.214 | 0.981 | 17.638 | 0.661 | 42.074 | 16.03 | 0 | 0 | 23.98 | 18.328 | 10.833 |
| Operating Expenses
| 232.124 | 160.259 | 181.538 | 228.065 | 287.494 | 415.905 | 387.565 | 313.754 | 233.993 | 220.223 | 267.68 | 222.042 | 132.013 | 104.623 | 108.872 | 78.137 | 68.079 |
| Operating Income
| 209.036 | 250.337 | 232.259 | 142.94 | 120.123 | -238.892 | -77.385 | -51.87 | -102.088 | -169.37 | -252.002 | -72.762 | -66.142 | -60.766 | -72.77 | -55.921 | -57.615 |
| Operating Income Ratio
| 0.472 | 0.61 | 0.561 | 0.367 | 0.28 | -0.689 | -0.259 | -0.189 | -0.683 | -2.216 | -11.014 | -0.484 | -1.004 | -1.386 | -2.016 | -2.517 | -5.506 |
| Total Other Income Expenses Net
| -1,157.105 | 2.085 | -31.602 | -34.079 | -61.18 | -145.618 | 26.017 | -2.059 | -27.566 | 0.661 | -20.81 | 0.138 | 0.9 | 1.411 | -0.607 | -0.9 | 0.6 |
| Income Before Tax
| -948.069 | 252.422 | 200.657 | 108.861 | 58.943 | -282.368 | -116.937 | -81.708 | -142.669 | -189.618 | -272.812 | -72.624 | -64.849 | -59.355 | -73.608 | -55.031 | -53.16 |
| Income Before Tax Ratio
| -2.141 | 0.615 | 0.485 | 0.279 | 0.138 | -0.815 | -0.392 | -0.298 | -0.954 | -2.481 | -11.923 | -0.483 | -0.984 | -1.353 | -2.039 | -2.477 | -5.08 |
| Income Tax Expense
| 83.49 | 77.357 | -327.791 | 2.685 | 74.257 | -5.752 | 34.259 | 37.984 | 19.023 | 8.578 | -11.729 | -11.325 | 0.003 | -2.944 | -0.296 | -0.823 | -0.145 |
| Net Income
| -1,002.239 | 175.065 | 528.448 | 106.176 | -15.314 | -282.368 | -116.937 | -81.708 | -142.669 | -189.618 | -272.812 | -72.624 | -64.852 | -52.981 | -71.185 | -53.874 | -52.752 |
| Net Income Ratio
| -2.264 | 0.426 | 1.277 | 0.273 | -0.036 | -0.815 | -0.392 | -0.298 | -0.954 | -2.481 | -11.923 | -0.483 | -0.985 | -1.208 | -1.972 | -2.425 | -5.041 |
| EPS
| -6.45 | 1.13 | 3.26 | 0.67 | -0.098 | -1.85 | -0.79 | -0.56 | -1 | -1.39 | -2.35 | -0.68 | -0.65 | -0.59 | -10 | -7.82 | -7.41 |
| EPS Diluted
| -6.45 | 0.94 | 3.21 | 0.66 | -0.098 | -1.85 | -0.78 | -0.56 | -1 | -1.39 | -2.35 | -0.68 | -0.65 | -0.59 | -0.94 | -7.82 | -0.7 |
| EBITDA
| 210.611 | 259.838 | 232.941 | 159.85 | 120.42 | -93.906 | -102.481 | -40.684 | -84.45 | -169.37 | -252.002 | -72.762 | -55.687 | -62.177 | -67.277 | -50.948 | -51.766 |
| EBITDA Ratio
| 0.476 | 0.633 | 0.563 | 0.41 | 0.281 | -0.271 | -0.344 | -0.149 | -0.565 | -2.216 | -11.014 | -0.484 | -0.845 | -1.418 | -1.864 | -2.293 | -4.947 |